Abstract
MicroRNAs (miRNAs) are de-regulated in cancer versus the normal tissue counterpart and actively participate in human carcinogenesis. Among the genes whose expression is under their control there are both oncogenes and tumor suppressor genes, revealing that it is not only limiting but simply wrong to assign them a function just as oncogenes or as tumor suppressor genes. In addition to primary tumors, miRNAs can be detected in almost all human body fluids and effectively help to diagnose cancer and to prognosticate clinical outcome and response to treatment of tumors. The advent of miRNA mimic and miRNA silencing molecules has allowed to modulate miRNA expression in tumors, showing that miRNAs can be effectively used as therapeutic agents. This review will focus on those findings that have provided the rationale for the use of miRNAs as patient “tailored” anti-cancer agents.
Keywords: Biomarker, cancer, drug resistance, microRNA, oncogene, therapy, tumor suppressor gene.
Current Molecular Medicine
Title:MicroRNAs and Cancer: Towards a Personalized Medicine
Volume: 13 Issue: 5
Author(s): M. Fabbri
Affiliation:
Keywords: Biomarker, cancer, drug resistance, microRNA, oncogene, therapy, tumor suppressor gene.
Abstract: MicroRNAs (miRNAs) are de-regulated in cancer versus the normal tissue counterpart and actively participate in human carcinogenesis. Among the genes whose expression is under their control there are both oncogenes and tumor suppressor genes, revealing that it is not only limiting but simply wrong to assign them a function just as oncogenes or as tumor suppressor genes. In addition to primary tumors, miRNAs can be detected in almost all human body fluids and effectively help to diagnose cancer and to prognosticate clinical outcome and response to treatment of tumors. The advent of miRNA mimic and miRNA silencing molecules has allowed to modulate miRNA expression in tumors, showing that miRNAs can be effectively used as therapeutic agents. This review will focus on those findings that have provided the rationale for the use of miRNAs as patient “tailored” anti-cancer agents.
Export Options
About this article
Cite this article as:
Fabbri M., MicroRNAs and Cancer: Towards a Personalized Medicine, Current Molecular Medicine 2013; 13 (5) . https://dx.doi.org/10.2174/1566524011313050006
DOI https://dx.doi.org/10.2174/1566524011313050006 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Pharmacotherapy for the Metabolic Syndrome
Current Vascular Pharmacology Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Overview of Coumarins and its Derivatives: Synthesis and Biological Activity
Letters in Organic Chemistry Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets A Method for Analyzing Two-locus Epistasis of Complex Diseases based on Decision Tree and Mutual Entropy
Current Proteomics A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals Role of Pentacyclic Triterpenoid Acids in the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Regenerative Medicine Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry GABA System as a Target for New Drugs
Current Medicinal Chemistry Trimethylamine: Metabolic, Pharmacokinetic and Safety Aspects
Current Drug Metabolism Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design